Whilst treatment with fibric-acid derivatives is usually associated with an increase in highdensity lipoprotein (HDL) cholesterol, a few hyperlipidaemic patients have shown a paradoxical fall.':" In these patients the profound hypoalphalipoproteinaemia has been induced by ciprofibrate, 1.47 bezafibratef-? or fenofibrate.' This effect may depend on the dose" and its absence of reproducibility in some patients suggests an interaction between the drug and other factors." Simultaneously with the decrease in HDL-cholesterol, a profound reduction in apolipoprotein AI (apoAI) is also seen. Whether the reduction in apoAI results from reduced synthesis or increased breakdown or both has not yet been established.
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We have therefore studied the metabolism of apoAI and apoAll in a patient in whom ciprofibrate at a daily dose of 200 mg had produced a reproducible reduction in HDL cholesterol.
CASE REPORT
The patient was a 45-year-old man initially prescribed ciprofibrate by his general practitioner for mixed hyperlipidaemia. Following minimal effect of 100 mg/day, the dose was increased to 200 mg and results 3 months later showed a virtually undetectable serum HDL cholesterol concentration, at < 0·1 mmol/L, and an apoAI concentration of < 0·25 g/L, Six weeks after cessation of therapy results had returned to pre-treatment levels, with HDL cholesterol at 0·85 mmol/L and apoAI at 1·36 giL. Subsequent rechallenge and cessation produced a similar course of events, and the patient remained Correspondence: GLue. E-mail: Gerald.Lucenpasteur-lille.fr asymptomatic and liver function tests were normal throughout this period. After a further rechallenge with 200mg/day for 8 weeks showed the HDL to have fallen once again, a turnover study was performed and repeated 3 months after stopping the ciprofibrate. The results were compared with those of five normolipidaemic subjects.
TURNOVER STUDY PROTOCOL AND METHODS
The turnover studies were carried out to determine the metabolic parameters of apoAI and apoAII in HDL. The procedure was performed by endogenous labelling, using amino acid labelled by stable isotope as previously described." After a 12-hour fast the subjects were given a priming bolus injection of 8 J.lmol/kg body weight of 5,5,5 2H rleucine (D3-leucine) (Isotec, Inc, Miamisburg OH, USA), immediately followed by a constant infusion of 10 umol/kg body weight of D3-leucine for 12 h. Blood samples were drawn from the opposite arm before the priming bolus, and at regular time intervals until the end of the infusion. A total of 10 blood samples were available for kinetic analysis. The subjects continued to fast during the infusion.
Plasma was immediately separated by centrifugation at 4°C. Very-low-density lipoprotein (VLDL; density < 1·006 g/mL) and HDL (density 1'063-1·210 g/rnl.) were separated by sequential ultracentrifugation. ApoBlOO, apoAI and apoAII were purified by preparative electrophoresis in the presence of sodium dodecyl sulphate (SDS) from VLDL and HDL, respectively. Proteins were hydrolysed and the purified amino acid mixtures were modified by esterification and bound to heptafluorobutyric anhydride (HBFA). They were injected into a gas-chromatogram coupled to a mass spectrometer (Finnigan-mat SSQ710B instrument, Finningan-Mat, San Jose CA, USA) using negative chemical ionization and methane as the reactant gas. The selected charged ions with a m/z of349 for leucine and 352 for D3-leucine were monitored and the tracer-to-tracee ratio was then determined.
The tracer-to-tracee ratios of apoAI and apoAII were fitted to monoexponential functions using SAAM II software (SAAM Institute, University of Washington, Seattle WA, USA).9
The function was defined as:
where At and Ap are the tracer-to-tracee ratio at time t and the precursor tracer-to-tracee ratio for the apolipoprotein, respectively, k is the fractional synthetic rate (FSR) and d is the delay. The precursor tracer-to-tracee ratio corresponds to the leucine ratio in the cytoplasm of hepatocytes and was determined by the plateau of the tracerto-tracee ratio of VLDL-apoB100 in normolipidaemic subjects. As this ratio did not reach a plateau during the patient infusion, the precursor ratio was measured as the D3-and DO-ketoisocaproic acid (KIC) ratio, an equivalent ratio of the leucine precursor pool. The KIC ratio was measured in plasma according to Ford et al. lD The subjects being under steady state conditions, the FSR is equal to the fractional catabolic rate (FCR). Apolipoprotein production rates (PR) were determined using the formula: PR = (FSR x plasma apolipoprotein concentration x plasma volumej/tbody weight). Plasma volume was assumed to be 0·04 L/kg of body weight.
Cholesterol and triglyceride levels were determined by automatic enzymatic procedures (Boehringer Mannheim, Mannheim, Germany) adapted to a Hitachi 705 analyser (Boehringer Mannheim). Cholesterol was measured in the HDL-containing supernatant after phosphotungstate/magnesium chloride precipitation of apoB-containing lipoproteins (Boehringer Mannheim). ApoAI and ApoB were quantified by laser immunonephelometry (Behring, Marburg, Germany). ApoAII was measured by noncompetitive immunoassay.
RESULTS
Fasting lipids serum samples from the patients receiving ciprofibrate and from the patients 3 months after stopping ciprofibrate treatment showed respectively total cholesterol concentrations of 7-42 and 6·02 mmol/L, a triglyceride of 5·10 and 7·98 mmol/L, HDL-cholesterol of 0·34 and 0·82 mmol/L, apoAI of 0-43 and 1·17 g/L, and apoAII of 0·14 and O· 55 giL. Stopping ciprofibrate produced a significant increase in Ann Clin Biochem 1999: 36 residence time of apoAI from 0·69 to 1·82 days and of apoAII from 2·00 to 3·45 days. Simultaneously, the apoAI production rate remained constant at 25·0 and 25·7 mg/kg.day whereas for apoAII it increased from 2·8 to 6·4mg/kg.day. Using the same methodology in normolipidaemic subjects, residence times and production rates were respectively 5·30 days and 9·01 mg/kg.day for apoAI and 6·11 days and 1·66 mg/kg.day for apoAII.
DISCUSSION
In this patient basal lipid metabolism was already perturbed, with increased production rates but an even greater reduction in residence times of both apoAI and All contributing to low apoAI and HDL-cholesterol concentrations. Similar changes have previously been observed in hypertriglyceridaemic subjects but not to the same extent.I'i'?
The metabolic parameters were calculated using methodology validated by comparison with radiolabelled apolipoproteins.'! Determination of apoAI and apoAII enrichments during the 12-h infusions did not permit us to evaluate whether the changes in apoAI and apoAII kinetics corresponded to those of the fast or slow turnover pools as described by Fisher et al. 14 Since this would have required determinations over a period of 250 h and the physiological identity of these pools was not defined, the knowledge of these precise modifications was not pursued in our patient.
The paradoxical decrease in apoAI following ciprofibrate therapy appears to be due to a further increase in its catabolism whilst the decrease in apoAII was due to both a significant reduction in synthesis as well as an increase in catabolism. This is in stark contrast to previous kinetic studies in hyperlipidaemic subjects, which suggested that fibric acid derivatives such as fenofibrate and gemfibrozil increase the production rates of apoAI and apoAII,15.16 although Shepherd et al. showed no effect using bezafibrate.!? In addition, the residence time either did not change or slightly decreased in patients treated with these drugs.
In our patient, and possibly others with the anomalous fibrate response, it appears that the unexpected fall in HDL-cholesterol may relate to both decreased synthesis and increased catabolism of apoA-containing lipoproteins. Further work is being undertaken to try and elucidate the underlying mechanisms that may be involved.
